Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000702428 | SCV000831283 | uncertain significance | Long QT syndrome | 2022-08-16 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 579200). This variant has not been reported in the literature in individuals affected with SNTA1-related conditions. This variant is present in population databases (rs754242619, gnomAD 0.01%). This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 341 of the SNTA1 protein (p.Ala341Thr). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002422578 | SCV002676407 | uncertain significance | Cardiovascular phenotype | 2023-11-30 | criteria provided, single submitter | clinical testing | The p.A341T variant (also known as c.1021G>A), located in coding exon 5 of the SNTA1 gene, results from a G to A substitution at nucleotide position 1021. The alanine at codon 341 is replaced by threonine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002477620 | SCV002777215 | uncertain significance | Long QT syndrome 12 | 2021-08-12 | criteria provided, single submitter | clinical testing |